Medullary Carcinoma Clinical Trials

8 recruitingLast updated: June 18, 2026

There are 8 actively recruiting medullary carcinoma clinical trials across 3 countries. Studies span Phase 2, Not Applicable, Phase 1. Top locations include Los Angeles, California, United States, Houston, Texas, United States, Bethesda, Maryland, United States. Updated daily from ClinicalTrials.gov.


Medullary Carcinoma Trials at a Glance

8 actively recruiting trials for medullary carcinoma are listed on ClinicalTrialsFinder across 6 cities in 3 countries. The largest study group is Phase 2 with 4 trials, with the heaviest enrollment activity in Los Angeles, Houston, and Bethesda. Lead sponsors running medullary carcinoma studies include M.D. Anderson Cancer Center, National Cancer Institute (NCI), and Giuseppe Procopio.

Browse medullary carcinoma trials by phase

Treatments under study

About Medullary Carcinoma Clinical Trials

Looking for clinical trials for Medullary Carcinoma? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Medullary Carcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Medullary Carcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 18 of 8 trials

Recruiting
Phase 2

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Stage IV Renal Cell Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8Large Cell Neuroendocrine Carcinoma+42 more
National Cancer Institute (NCI)314 enrolled578 locationsNCT03866382
Recruiting
Phase 2

Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...

Small Cell Carcinoma of the BladderSmall Cell Carcinoma of the Urinary TractSquamous Cell Carcinoma of the Bladder+5 more
National Cancer Institute (NCI)60 enrolled1 locationNCT06161532
Recruiting
Phase 2

Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies

Epithelioid SarcomaSMARCB1-Deficient MalignanciesMedullary Carcinoma
M.D. Anderson Cancer Center40 enrolled1 locationNCT06444880
Recruiting

Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors

Malignant Brain NeoplasmMalignant Solid NeoplasmMalignant Testicular Neoplasm+97 more
University of Southern California250 enrolled2 locationsNCT07259304
Recruiting

Natural History of Medullary Thyroid Cancer to Inform Advanced Disease Management

Stage III Thyroid Gland Medullary Carcinoma AJCC v8Advanced Thyroid Gland Medullary CarcinomaStage IV Thyroid Gland Medullary Carcinoma AJCC v8+3 more
M.D. Anderson Cancer Center2,030 enrolled2 locationsNCT04216732
Recruiting
Not Applicable

Patient Decision Aid in Supporting Decision-Making About When to Start or Stop New Drugs, Join Clinical Trials, or Continue Active Surveillance in Patients With Medullary Thyroid Cancer and Their Caregivers

Thyroid Gland Medullary Carcinoma
M.D. Anderson Cancer Center120 enrolled1 locationNCT03892993
Recruiting
Phase 2

Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma

Collecting Duct CarcinomaRenal Medullary CarcinomaBellini Carcinoma
Giuseppe Procopio23 enrolled1 locationNCT06302569
Recruiting
Phase 1

Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers

Breast CarcinomaUrothelial CarcinomaOvarian Carcinoma+31 more
Jonsson Comprehensive Cancer Center30 enrolled1 locationNCT07118176